DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies: clinical results and possible mechanisms of action.
Lübbert
M
M
Department of Medicine, University of Freiburg Medical Center, Germany. luebbert@mml1.ukl.uni-freiburg.de
D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D001374:Azacitidine / Q000031:analogs & derivatives / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D019175:DNA Methylation / Q000187:drug effects*; D015254:DNA Modification Methylases / Q000037:antagonists & inhibitors*; D000077209:Decitabine; D006453:Hemoglobinopathies / Q000188:drug therapy*; D006801:Humans; D007938:Leukemia / Q000188:drug therapy*; D009190:Myelodysplastic Syndromes / Q000188:drug therapy*
D000964:Antimetabolites, Antineoplastic; D000077209:Decitabine; D015254:DNA Modification Methylases; D001374:Azacitidine